Farmas USA

ADXS

Advaxis (ADXS) Launches MINE Collaboration with MSK Cancer Center

http://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Launches+MINE+Collaboration+with+MSK+Cancer+Center/11004969.html?si_client=intbro

OFF-TOPIC

Hace un mes comenté mi entrada en un fondo de inversión de renta global. Fue buena entrada. Ya me va dando un 8%.

Todos compramos pensando que están en "superoferta"! Pero luego resulta que al día siguiente las encuentras a 2x1...

GALE

On October 23, 2015, Orexo AB (“Orexo”) and Galena Biopharma, Inc. (the “Company”) entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (“Actavis”) to resolve pending patent litigation brought by Orexo against Actavis involving Abstral® (fentanyl) sublingual tablets. The pending patent litigation was filed by Orexo in the U.S. District Court for the District of New Jersey in response to Actavis’ submission of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (“FDA”), seeking marketing approval for a generic version of Abstral. As a result of the settlement and license agreement, Actavis will be permitted to enter the market with a generic or authorized generic version of Abstral in the United States in June 2018 or earlier under certain circumstances. The parties will request that the Court enter orders dismissing with prejudice the litigation referred to above against Actavis. Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law. The expiration date for the latest expiring Abstral patent listed in the FDA’s Orange Book is September 2019.

http://investors.galenabiopharma.com/secfiling.cfm?filingid=1390478-15-40&CIK=1390478

VRX

Vendida toda mi posición, con pérdida.. sigo sin encontrar mi camino en las últimas semanas...

Pues para!

A veces solo es cuestion de PARAR y estar unos dias solo mirando , observando ... agazapado ... no buscando la oportunidad que a veces forzamos sino esperando a que ésta se presente.

IBB velas 1h

cabalas y mas cabalas bullish ... la otra opcion ya la conocemos, de vuelta a los 297 ,, y si pensamos en la dichosa bear flag en diario ... a los 250 al menos

Me sumo a la recomendación de Framus.

Y salen mas osos de la madriguera, framus que les hacemos, ? no los comemos. pero que conste que no es la única , ya voy por la 4ta que le veo este dato incrementado podría estar así una buen parte del sector , pero si en una se ha incrementado mas significativamente que otras
-----------------
The short interest in Novavax, Inc. (NASDAQ:NVAX) has increased from 27,733,968 on September 30,2015 to 29,996,871 on October 15,2015. The change was measured at 2,262,903 shares or 8.2%. The leftover shorts were 11.3% of the floated shares. The days to cover are 4, given the average daily volume of 7,308,532 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on October 26th.

http://newswatchinternational.com/news/short-interest-update-on-novavax-inc.html